DAX24.292 +1,4%Est505.882 ±0,0%MSCI World4.343 -0,1%Top 10 Crypto9,8000 +1,4%Nas25.114 +0,9%Bitcoin68.398 +2,1%Euro1,1727 -0,2%Öl108,4 -0,8%Gold4.613 -0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Infineon 623100 SAP 716460 Amazon 906866 Lufthansa 823212 Microsoft 870747 Siemens Energy ENER6Y Alphabet A (ex Google) A14Y6F Volkswagen (VW) vz. 766403 Allianz 840400 Berkshire Hathaway A0YJQ2 Deutsche Telekom 555750 BASF BASF11 NEL ASA A0B733
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach EZB-Entscheid: DAX geht über 24.000-Punkte-Marke ins lange Wochenende -- Apple meldet starke Zahlen -- Reddit, Rivian, VW, RTL, Eli Lilly, Novo Nordisk im Fokus
Top News
Direct Indexing vs ETF: Was hinter der angeblichen Konkurrenz wirklich steckt Direct Indexing vs ETF: Was hinter der angeblichen Konkurrenz wirklich steckt
Neues Bullenmarkt-Szenario für XRP? Fundamentaldaten und Prognosen im Überblick Neues Bullenmarkt-Szenario für XRP? Fundamentaldaten und Prognosen im Überblick
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

UCB Aktie

Kaufen
Verkaufen
114,00 EUR +67,00 EUR +142,55 %
STU
finanzen.net zero
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone
KGV30,30Div. Rendite0,37%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA14WZY

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS9034801012

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolUCBJY

UCB Aktien News

DatumMeistgelesen
PR NewswireUCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
PR NewswireUCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
PR Newswire/C O R R E C T I O N -- UCB/
PR NewswireU.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
PR NewswireUCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
PR NewswireUCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
PR NewswireBIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
PR NewswireResults published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
PR NewswireBIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
PR NewswireBIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
PR NewswireGen Z and Millennial Patients with Chronic Rheumatic Diseases Are Opening Up to Raise Awareness for Improved Care
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
PR NewswireUCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
PR NewswireUCB extends its BIMZELX® "Get Yourself Back" direct-to-consumer campaign for the hidradenitis suppurativa community
PR NewswireUCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
PR NewswireUCB presents latest thymidine kinase 2 deficiency (TK2d) research at the United Mitochondrial Disease Foundation (UMDF) 2025 Conference
PR NewswireInaugural 2025 UCB U.S. Myasthenia Gravis Scholarship™ grants 15 scholarships to people impacted by myasthenia gravis in the U.S.
PR NewswireUCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
PR NewswireBIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
PR NewswireUCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
PR NewswireUCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
GlobeNewswireUCB Convening Notice to the General Meeting of the Shareholders 2025
PR NewswireNew data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
PR NewswireEpilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
PR NewswireBIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
PR NewswireBIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
PR NewswireOn Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
PR NewswireUCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
PR NewswireUCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
PR NewswireUCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
PR NewswireUCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
PR NewswireNew BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB's Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
PR NewswireUCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) S...
PR NewswireUCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
PR NewswireUCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
PR NewswireUCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
PR NewswireUCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

UCB News

UCB News: auf dieser Seite finden Sie alle UCB News und Nachrichten zur UCB Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch UCB News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um UCB News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.